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Dear Editors,
After observing an increased incidence of imprecise and sometimes erroneous
use of nuclear chemistry, radiochemistry and radiopharmacy related terms and no-
menclature in scientific reports, an international working group of experts was as-
sembled to address the issue. Upon extensive consultation with peers within the
field of radiochemistry and radiopharmaceutical sciences over a 3-year period and
an open discussion, consensus was achieved during the International Symposium
on Radiopharmaceutical Sciences in May 2017 in an open forum. The resulting,
harmonised nomenclature recommendations have now been published with follow-
ing aims given therein (Coenen et al. 2017):
 Provide a reference source for nomenclature good practice in the
radiopharmaceutical sciences.
 Clarify the use of terms and rules concerning exclusively radiopharmaceutical
terminology, i.e. nuclear- and radiochemical terms, symbols and expressions.
 Address gaps and inconsistencies in existing radiochemistry nomenclature rules.
 Provide source literature for further harmonisation beyond our immediate peer
group (publishers, editors, IUPAC, pharmacopoeias, etc.).
In order to disseminate further the consensus recommendations, a summary (see
below) has been prepared for ease of reference and for open dissemination across the
field. We hope that your journal will consider incorporating these guidelines as part of
your journals manuscript preparation instructions.
Yours sincerely,
International consensus nomenclature guidelines – Summary
Measures of radioactivity
Unit of activity
“Radioactivity” is a physical phenomenon, defined as the property of certain nuclei to
spontaneously fragment or rearrange, resulting in the emission of radiation.
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“Activity” is the quantitative measure of radioactivity: The number of nuclear decays,
occurring in a given quantity of material over a certain time interval, divided by that
time interval.
“Becquerel” (Bq) is the agreed SI derived unit for the quantity of activity.
Pre-SI units (e.g. imperial units) (e.g. mCi, Ci) can also be used, but must be placed
in parentheses after the stated SI units.
N.B.: The correct terms “radioactive” and “non-radioactive” must not be replaced by
the lab-jargon “hot” and “cold”, respectively, in public or official documents.
Molar activity (Am) and specific activity (As)
"Molar activity" is the measured activity per mole of compound; measured in Bq/mol
(GBq/μmol).
"Specific activity" is the measured activity per gram of compound; measured in Bq/
g (GBq/μg).
Due to radioactive decay, the instant of time of measurement must be stated; for ex-
ample: “The molar activity was 50 GBq/μmol 2 h after the end of synthesis”.
Apparent molar activity and apparent specific activity
The terms "apparent molar activity" and "apparent specific activity" take into account
the amounts of the labelled and non-radiolabelled impurities present (using moles, or
weight, respectively).
Effective molar activity and effective specific activity
The terms “effective molar activity” and “effective specific activity” address the chemically,
biologically or pharmacologically ‘active’ fraction of radioactive and non-radioactive mate-
rials in a sample, competing with the labelled product in its chemical or biological reactions.
In this case, the “effectivity” must be determined by an additional analytical process;
e.g. receptor or enzyme binding assay, side-product analysis, etc.
Other terms like “pseudo-specific activity” etc. must not be used.
‘No-carrier-added’, ‘carrier added’ and ‘carrier-free’
The non-quantitative terms, “no-carrier-added” (n.c.a.) and “carrier-added” (c.a.) can be
used as a practical, qualitative indication of specific or molar activity.
The term “carrier-free” (c.f.) can only be used in the rare case where the theoretical
maximum specific or molar activity is unambiguously proven.
Measures involving determination of amounts of material (e.g. molar activity or
radiochemical purity) should be accompanied by a clear description of the method of
detection.
Radionuclide and radioisotope descriptors
The enrichment of a chemical compound with an isotope (stable or radioactive) of one
or more of the elements, of which it is constituted, is indicated by the symbol of the
element (E) together with its mass number (A) (as a superscript in front) within square
brackets, [AE], immediately preceding the compound’s name or chemical formula.
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Example: [2H,14C] benzene, or [2H,14C]C6H6, represent the compound benzene,
enriched or labelled, with stable deuterium and radioactive carbon-14, respectively.
For rules designating labelling positions (e.g. L-[methyl-11C] methionine or L-[carbox-
yl-11C]methionine) see: http://goldbook.iupac.org/pages/about.html.
These rules apply equally to organic, inorganic and organometallic compounds and com-
plexes: e.g. [223Ra]RaCl2, [
99mTc]NaTcO4, [
99mTc]Tc-MDP, [68Ga]Ga-DOTA-TATE, etc.
As square brackets are also used to denote metal complexes, care should be taken to
avoid confusion with radionuclide descriptors, e.g. [99mTc][Tc (CO)3(OH2)3]
+, [111In][In
(DTPA)]2−, etc.
N.B.: The symbol for isotopic enrichment [AE] should be treated like a syllable, and
thus only be hyphenated at the end of a line of text.
Conversely, do not use nuclide symbols in square brackets in combination with
nouns and verbs.
Examples of the use of square brackets and hyphens:
Correct Incorrect
L-[13N] alanine, (S)-[13N]alanine [13N]L-alanine, (S)-13N-alanine, L-[13N]-alanine
[18F]fluorobenzene [18F]benzene (no fluorine atom in benzene)
[99mTc]TcDTPA2− [99mTc]DTPA2−, 99mTc-DTPA2− (no Tc in chelator)
11C-compound, 125I-substitution, 18F-derivative,
68Ga-conjugate, 77Br-reagent
[11C]compound, [125I]-substitution, [18F]-derivative,
[68Ga]conjugate (no chemical compound names)
11C-labelling, 64Cu-labelling, 18F-fluorination
(with hyphen!)
[11C]labelling, [64Cu]-labelling, [18F]-(radio)-fluorination (no
chemical compound names)
The terms ‘(radio)isotope’ and ‘(radio)nuclide’ are often used incorrectly in texts,
inferring “isotope” means “radioactive nuclide” or even “labelled compound”.
– ‘Nuclide’ indicates an atom, characterised by its numbers of protons (identifying its
elemental nature) and of nucleons (indicating its mass).
– ‘Isotopes’ are nuclides of the same element (same proton number), but having
different numbers of neutrons (hence different atomic mass).
– Isotopic nuclides of different energy state are called isomeric nuclides, isomeric
isotopes or ‘isomers’, such as technetium-99g and -99m.
N.B.: All (radio)isotopes are (radio)nuclides, while the reverse is not true!
Radiochemical yield (RCY)
The “radiochemical yield” is the amount of activity in the product expressed as the
percentage (%) of related starting activity utilized in the considered process (e.g.
synthesis, separation, etc.). The quantity of both must relate to the same radionuclide
and be decay corrected to the same point in time before the calculation is made.
(Reported measures of RCY should indicate, whether a product was isolated or not.)
Colloquial expressions for “radio-yield” found in literature, e.g. ‘radiochemical
conversion’, ‘analytical radiochemical yield’, ‘radio-HPLC yield’ must not be used as a
surrogate for ‘radiochemical yield’ or ‘radiochemical purity’, respectively.
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The following text may serve as examples for good practice, when describing a
radiochemical yield:
“The radiochemical yield was 67% (based on HPLC analysis of the crude product).”
“The radiochemical yield* of “Y” was 67%”, with the following as a footnote:
– *“determined by radio-HPLC analysis of the crude product”, or
– *“non-isolated, estimated by radio-HPLC”,
or, in the general experimental section: “All radiochemical yields were determined by
HPLC of the crude product, unless stated otherwise.”,
or alternatively use: “The radiochemical purity of the crude product was 67%.”,
or: “The radiochemical yield of “Y” determined from an aliquot of the reaction
solution amounted to 67%.”,
or: “The radiochemical yield of crude “Y” was 67% based on the amount of activity
eluted from the HPLC column.”
Expressions such as ‘conversion’ or ‘incorporation’, however, may be used in a
semantic sense and even be indispensable in context of mechanistic discussions.
For example, “The ‘conversion’ (or ‘incorporation’) proceeded with a 50% yield”.
Here it is clear from the context, that the radiochemical yield of the conversion is
intended.
Activity yield
The “activity yield” is the amount of radioactive product expressed in Bq (MBq, GBq),
which is obtained from a starting amount of activity (e.g. produced at a cyclotron) and is
not corrected for decay.
This term is useful, or necessary to indicate the efficiency of a labelling
procedure. The activity yield is, of course, dependent on the effectiveness and
duration of all technical manipulations used, in addition to the yield of the
labelling reaction.
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